As a result, most of the funds, which emphasize fledgling, developmental biopharma companies, are now in the red for the year at the same time the broader market is up by double digits. Keep in mind that most of the life sciences and biopharma funds are essentially small-cap long-only funds — not exactly a great place to be in the market this year in general.
Casdin
